$3.00, keep dreaming, additional “Pump and Dump” lawsuit filed for hyping Covid-19 testing in NY, NJ and Chicago, Google it and be enlightened. Testing in most states is free of charge and done within the confines of the hospitals own lab mainly because outside testing facilities tests take too long to report results and sample has to be shipped to Opko’s NJ lab which only has the capacity to run 5,000 tests a day. Early in March when announced Opko would be testing for Covid-19 the stock spiked to a 52 week high of $2.90, yes, this was great news but then the truth came out and now you have a share price where it should be, @$1.15 and the only way it’s over a dollar is because PF keeps buying to screw all the shorts. Bio reference doesn’t make very much money for Opko and sales of Rayaldee 3 years post launch at $12m a quarter provide no reason to celebrate.
What would get the stock over $3.00 is the HGH program’s positive phase 3B study results and FDA approval but that’s not going to happen anytime soon, if at all. Sweet dreams.